Now Reading
European Commission approves Imvanex smallpox vaccine for monkeypox
Subscribe
Sign In

European Commission approves Imvanex smallpox vaccine for monkeypox

EU approves Imvanex vaccine for monkeypox. Imvanex vaccine label extended to include monkeypox.

Where: World

The Facts

On July 25th, Danish biotechnology company Bavarian Nordic announced that the European Commission had authorized the marketing of their Imvanex smallpox vaccine as protection against monkeypox and disease caused by the vaccinia virus.
The European Medicines Agency recommended the label extension for the Imvanex vaccine last week.
According to Bavarian Nordic, the approval is valid in all member states of the European Union, Iceland, Liechtenstein, and Norway.
The EU approved the Imvanex vaccine for smallpox prevention in 2013. Imvanex is the only vaccine approved for monkeypox prevention in the US and Canada.
The CDC state that the monkeypox and smallpox viruses belong to the same family. While the two diseases have similar symptoms, monkeypox has milder symptoms, is less contagious, and is rarely fatal.

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.

© 2021 Citable. All Rights Reserved.